According to one study, people living with HIV (PLHIV) are less likely to receive appropriate statin therapy for the prevention of atherosclerotic cardiovascular disease (ASCVD).
“This is important given the increased risk of ASCVD in this population, and strategies that address this gap in care should be explored,” the researchers said.
This retrospective study aimed to assess statin eligibility and prescribing patterns among patients at an HIV treatment and internal medicine clinic in an urban academic medical center from June to September 2018 using guidelines from the American College of Cardiology/American Heart Association on Treating Blood Cholesterol to Reduce ASCVD Risk.
Investigators assessed patient eligibility and actual treatment with appropriate statin therapy. They also compared the characteristics of appropriately and inappropriately treated patients using the chi-square test; predictors for receiving appropriate statin therapy were discovered using logistic regression.
Of the 300 participants included in the analysis, 221 were eligible for statins. Of note, there were fewer statin-eligible PHAs receiving current statin intensity for their risk-benefit group compared to the uninfected control group (30.2% vs. 67.0%; p
Multivariate analyzes revealed that PLHIV were significantly disadvantaged in terms of appropriate statin treatment. In contrast, polypharmacies were more likely to receive the appropriate treatment.
“Recent studies suggest that statins are under-prescribed in PLHIV at risk for ASCVD, but none have assessed whether eligible patients receive the correct statin and intensity compared to uninfected controls,” noted the investigators.